Get the Stockscreener App
28.69
4.46%
-1.34
After Hours:
28.69
Edgewise Therapeutics Inc stock is traded at $28.69, with a volume of 1.07M.
It is down -4.46% in the last 24 hours and up +8.02% over the past month.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.
See More
Previous Close:
$30.03
Open:
$29.99
24h Volume:
1.07M
Relative Volume:
1.29
Market Cap:
$2.72B
Revenue:
-
Net Income/Loss:
$-115.88M
P/E Ratio:
-18.55
EPS:
-1.5468
Net Cash Flow:
$-104.72M
1W Performance:
+2.46%
1M Performance:
+8.02%
6M Performance:
+78.53%
1Y Performance:
+46.15%
1-Day Range:
$28.22
$30.48
1-Week Range:
$27.20
$30.48
52-Week Range:
$14.90
$38.12
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Name
Edgewise Therapeutics Inc
Sector
Industry
Phone
720-262-7002
Address
1715 38TH ST, BOULDER
Compare EWTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
28.69 | 2.72B | 0 | -115.88M | -104.72M | -1.5468 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-25 | Initiated | Stifel | Hold |
| Nov-22-24 | Initiated | Evercore ISI | Outperform |
| Mar-07-24 | Initiated | Piper Sandler | Overweight |
| May-01-23 | Initiated | Truist | Buy |
| Aug-25-22 | Downgrade | Goldman | Neutral → Sell |
| Apr-13-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-28-22 | Initiated | Goldman | Neutral |
View All
Edgewise Therapeutics Inc Stock (EWTX) Latest News
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Edgewise Therapeutics' SWOT analysis: novel therapies drive stock potential - MSN
Can you now get a good deal on Edgewise Therapeutics Inc’s shares? - US Post News
When (EWTX) Moves Investors should Listen - Stock Traders Daily
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap UpStill a Buy? - MarketBeat
Ratios Uncovered: Breaking Down Edgewise Therapeutics Inc (EWTX)’s Trailing Twelve Months Metrics - The Dwinnex
Check out these key findings about Edgewise Therapeutics Inc (EWTX) - SETE News
Edgewise Therapeutics' SWOT analysis: novel therapies drive stock potential By Investing.com - Investing.com South Africa
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) CMO Joanne M. Donovan Sells 25,000 Shares - MarketBeat
Paradigm Biocapital Advisors LP Increases Stake in Edgewise Ther - GuruFocus.com
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Short Interest Update - MarketBeat
Moody Aldrich Partners LLC Has $5.02 Million Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics names new COO - MSN
Edgewise Therapeutics reshuffles executive team - MSN
Edgewise Therapeutics (NASDAQ:EWTX) Trading Up 7.1%Here's What Happened - MarketBeat
Edgewise elevates chief operating officer, hires development exec - BizWest
Edgewise Therapeutics Promotes Behrad Derakhshan, Ph.D., to Chief Operating Officer Role - Defense World
Why Is Andreas Halvorsen Bullish On Edgewise Therapeutics, Inc. (EWTX) Now? - Yahoo Finance
New COOs for Vividion, Edgewise - BioCentury
Edgewise rated as a new Hold at Stifel on a balanced risk-reward setup - MSN
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap DownWhat's Next? - MarketBeat
Edgewise Therapeutics names new COO By Investing.com - Investing.com Australia
Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development - BioSpace
Edgewise Therapeutics (NASDAQ:EWTX) Coverage Initiated by Analysts at Stifel Nicolaus - MarketBeat
Edgewise Therapeutics Strengthens Leadership Team, Appoints Merck Veteran as Chief Development Officer - StockTitan
Stifel initiates Edgewise Therapeutics stock with Hold rating, $30 target By Investing.com - Investing.com Canada
Stifel initiates Edgewise Therapeutics stock with Hold rating, $30 target - MSN
Short Interest in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Increases By 8.9% - Defense World
Edgewise Therapeutics Insiders Sold US$1.0m Of Shares Suggesting Hesitancy - Simply Wall St
JPMorgan Chase & Co. Boosts Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Purchased by JPMorgan Chase & Co. - Defense World
Edgewise Therapeutics (NASDAQ:EWTX) Stock Price Down 6.1%Should You Sell? - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
December 19th Options Now Available For Edgewise Therapeutics (EWTX) - Nasdaq
How to Take Advantage of moves in (EWTX) - Stock Traders Daily
Edgewise Therapeutics (NASDAQ:EWTX) Trading 7.4% HigherHere's What Happened - MarketBeat
Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025 - Business Wire
Edgewise Therapeutics Advances Muscular Dystrophy Drug Sevasemten, Nears Pivotal Trial Milestone - StockTitan
Edgewise Therapeutics Inc Stock (EWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):